Purpose of review: The aim of this review is to describe the value of high-dose polyclonal intravenous immunoglobulins as a treatment option in autoimmune disorders affecting the peripheral nervous system.
Recent findings: A randomized placebo-controlled trial in patients with chronic inflammatory demyelinating polyradiculoneuropathy revealed short-term and long-term efficacy and safety of intravenous immunoglobulins as a treatment option for the chronically inflamed peripheral nervous system. Case reports suggest that the subcutaneous administration of immunoglobulins may represent a convenient alternative.
Summary: Intravenous immunoglobulin represents an effective and safe treatment option in patients with autoimmune-mediated diseases affecting the peripheral nerves.